- Home
- JNVR vs CRBU Comparison
JNVR vs CRBU Comparison
Compare JNVR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- CRBU
- Stock Information
- Founded
- JNVR 2018
- CRBU 2011
- Country
- JNVR United States
- CRBU United States
- Employees
- JNVR N/A
- CRBU N/A
- Industry
- JNVR Finance: Consumer Services
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- JNVR Finance
- CRBU Health Care
- Exchange
- JNVR Nasdaq
- CRBU Nasdaq
- Market Cap
- JNVR 93.3M
- CRBU 93.0M
- IPO Year
- JNVR 2023
- CRBU 2021
- Fundamental
- Price
- JNVR $63.99
- CRBU $0.79
- Analyst Decision
- JNVR
- CRBU Strong Buy
- Analyst Count
- JNVR 0
- CRBU 5
- Target Price
- JNVR N/A
- CRBU $10.60
- AVG Volume (30 Days)
- JNVR 1.9M
- CRBU 1.0M
- Earning Date
- JNVR 05-13-2025
- CRBU 05-16-2025
- Dividend Yield
- JNVR N/A
- CRBU N/A
- EPS Growth
- JNVR N/A
- CRBU N/A
- EPS
- JNVR N/A
- CRBU N/A
- Revenue
- JNVR $2,099,660.00
- CRBU $9,994,000.00
- Revenue This Year
- JNVR N/A
- CRBU N/A
- Revenue Next Year
- JNVR N/A
- CRBU $163.34
- P/E Ratio
- JNVR N/A
- CRBU N/A
- Revenue Growth
- JNVR 4.82
- CRBU N/A
- 52 Week Low
- JNVR $3.37
- CRBU $0.66
- 52 Week High
- JNVR $91.38
- CRBU $4.21
- Technical
- Relative Strength Index (RSI)
- JNVR 57.60
- CRBU 44.91
- Support Level
- JNVR $64.09
- CRBU $0.77
- Resistance Level
- JNVR $91.38
- CRBU $0.91
- Average True Range (ATR)
- JNVR 14.99
- CRBU 0.08
- MACD
- JNVR -0.59
- CRBU 0.01
- Stochastic Oscillator
- JNVR 53.59
- CRBU 32.97
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from platform fees and subscription revenue.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.